Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanistic CMR Study of Empagliflozin in Heart Failure
2017-000376-28Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic heart failure (CHF), heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) comparing Empagliflozin with Placebo (2 arms). Primary endpoint: Change in myocardial PCr/ATP ratio at rest. Started May 2018; status: completed.
02
Drugs
empagliflozin
03
Conditions
chronic heart failure (CHF)heart failure with reduced ejection fraction (HFrEF)heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on 2017-000376-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000376-28.